title: RNA-mediated inhibition of HIV in a gene therapy setting.
abstract: At present, treatment for HIV-1 infection employs highly active anti-retroviral therapy (HAART), which utilizes a combination of RT and protease inhibitors. Unfortunately, HIV can escape many therapies because of its high mutation rate and the complexity of its pathogenesis. HIV-1 integrates into the cellular genome, which facilitates persistence and acts as a reservoir for reactivation and replication. As an alternative or adjuvant to chemotherapy we have been developing an RNA-based gene therapy approach for the treatment of HIV-1 infection. This article summarizes the various RNA based technologies that we have developed for potential application in a gene therapy setting.
authors.affiliation: Divisions of Molecular Biology, Beckman Research Institute of the City of Hope, Duarte, California 91010, USA.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Michienzi
authors.forename: Daniela
authors.initials: D
authors.lastname: Castanotto
authors.forename: Nancy
authors.initials: N
authors.lastname: Lee
authors.forename: Shirley
authors.initials: S
authors.lastname: Li
authors.forename: John A
authors.initials: JA
authors.lastname: Zaia
authors.forename: John J
authors.initials: JJ
authors.lastname: Rossi
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology*; D002466:Cell Nucleolus / Q000187:drug effects; D015316:Genetic Therapy / Q000379:methods*; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy*; D006412:Hematopoietic Stem Cells; D006801:Humans; D034622:RNA Interference / Q000187:drug effects; D016337:RNA, Catalytic / Q000494:pharmacology*; D034741:RNA, Small Interfering / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; D016337:RNA, Catalytic; D034741:RNA, Small Interfering